Results 11 to 20 of about 270,393 (395)

Eosinophils in eosinophilic pneumonia [PDF]

European Respiratory Journal, 1996
Idiopathic eosinophilic pneumonia (IEP) is an uncom-mon disease of unknown aetiology characterized by theaccumulation of eosinophils in the lung, variable bloodeosinophilia and peripheral opacities on the chest radio-gram. The response to steroid treatment is dramatic butrelapses are frequent, requiring the use of long-termsteroid treatment [1 ...
ALBERA, Carlo, P. GHIO
openaire   +2 more sources

Dermatomyositis with Eosinophils [PDF]

Dermatopathology, 2023
Dermatomyositis is an idiopathic inflammatory myopathy that often presents with symmetric proximal skeletal muscle weakness and characteristic skin findings. Typical skin biopsy findings include vacuolar changes of the basal layer, increased dermal mucin, and a predominantly lymphocytic infiltrate.
Isabella I. Sanchez, Henry O. Herrera, Ashley Elsensohn, Bonnie A. Lee, Christina N. Kraus   +4 more
openaire   +4 more sources

Eosinophilic fasciitis [PDF]

Anais Brasileiros de Dermatologia, 2016
Eosinophilic fasciitis is a rare sclerodermiform syndrome of unknown etiology. It is characterized by the thickening of the muscular fascia and subcutaneous tissue, with a variable infiltration of eosinophils. Peripheral eosinophilia, poly or monoclonal hypergammaglobulinemia and increased erythrocyte sedimentation rate can be seen.
Lamback, Elisa Baranski, Resende, Fernanda Simões Seabra, Lenzi, Thiara Cristina Rocha   +2 more
openaire   +5 more sources

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
I. Agache, Jessica Beltran, C. Akdis, M. Akdiş, C. Canelo-Aybar, W. Canonica, T. Casale, T. Chivato, J. Corren, S. D. Del Giacco, T. Eiwegger, D. Firinu, J. Gern, E. Hamelmann, N. Hanania, M. Mäkelä, I. H. Martín, Parameswaran Nair, L. O’Mahony, N. Papadopoulos, A. Papi, Hae‐Sim Park, L. A. Pérez de Llano, M. Posso, Claudio Rocha, S. Quirce, J. Sastre, M. Shamji, Yang Song, Corinna Steiner, J. Schwarze, P. Alonso-Coello, Ó. Palomares, M. Jutel   +33 more
semanticscholar   +1 more source

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Arthritis & Rheumatology, 2021
Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial.
A. Bettiol, M. Urban, L. Dagna, V. Cottin, F. Franceschini, S. Del Giacco, F. Schiavon, T. Neumann, G. Lopalco, P. Novikov, C. Baldini, C. Lombardi, A. Berti, F. Alberici, M. Folci, S. Negrini, R. Sinico, L. Quartuccio, C. Lunardi, P. Parronchi, F. Moosig, G. Espígol-Frigolé, J. Schroeder, A. Kernder, S. Monti, E. Silvagni, C. Crimi, F. Cinetto, P. Fraticelli, D. Roccatello, A. Vacca, A. Mohammad, B. Hellmich, M. Samson, E. Bargagli, J. C. Cohen Tervaert, C. Ribi, D. Fiori, F. Bello, F. Fagni, L. Moroni, G. Ramirez, M. Nasser, C. Marvisi, P. Toniati, D. Firinu, R. Padoan, A. Egan, B. Seeliger, F. Iannone, C. Salvarani, D. Jayne, D. Prisco, A. Vaglio, G. Emmi   +54 more
semanticscholar   +1 more source

Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation

Biomedicines, 2022
In recent years, tremendous efforts have been devoted to characterizing the inflammatory processes in chronic obstructive pulmonary disease (COPD) in order to provide more personalized treatment for COPD patients.
Balazs Antus, Imre Barta
doaj   +1 more source

Eosinophilic pustular folliculitis of infancy: A rare diagnosis in children

Clinical Case Reports, 2021
Remember EPFI as a differential diagnosis in children with a rash on the scalp and no effect of antibiotic treatment.
Anne Sofie Frølunde, Anne Braae Olesen, Rikke Riber‐Hansen, Kristine Appel Uldall Pallesen   +3 more
doaj   +1 more source

TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background

Biomedicines, 2022
A number of recently described renal tumor entities share an eosinophilic/oncocytic morphology, somewhat solid architectural growth pattern, and tendency to present as low-stage tumors.
Kristyna Pivovarcikova, Reza Alaghehbandan, Tomas Vanecek, Riuko Ohashi, Tomas Pitra, Ondrej Hes   +5 more
doaj   +1 more source

Steroids in pediatric eosinophilic esophagitis [PDF]

, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Eosinophilic Cholecystitis and Eosinophils in Gallbladder Injuries: A Clinicopathological Analysis of 1050 Cholecystectomies

Diagnostics, 2023
“Eosinophilic cholecystitis” has been an elusive concept. Around 1050 consecutive cholecystectomies with chronic (CC, n = 895), subacute (SAC, n = 100), and acute cholecystitis (AC, n = 55) were reviewed for eosinophilic infiltration.
Bahar Memis, Burcu Saka, Juan Carlos Roa, Sudeshna Bandyopadhyay, Michelle Reid, Pelin Bagci, Berk Kaan Aktas, Ayse Armutlu, Olca Basturk, N. Volkan Adsay   +9 more
doaj   +1 more source